Strategic Communication and Public Relations

Drug against psoriasis slows down cancer cell growth and metastasis

No. 28 | 12/08/2016

Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) are examining a promising agent against cancer of the immune system. In this type of cancer, the tumor cells have lost their ability to respond to signals that cause programmed cell death, or apoptosis. The new substance restores this ability, thus slowing down tumor growth and, above all, metastatic spread.

Immunofluorescence of a cutaneous T cell lymphoma after treatment with DMF (human lymphoma cells were transplanted into the skin of mice). Malignant cells are stained red, dying cells are stained green. In dying tumor cells, the colors superimpose and appear yellow. The huge number of yellow cells indicates that DMF efficiently kills tumor cells.
© Blood, Photo: Anne Schröder/Karin Müller-Decker

Cutaneous T-cell lymphomas present in the skin. They arise from transformed T cells, a type of immune system cells. A special form of this cancer is Sézary syndrome, for which there is no curative treatment to the present day. In patients with this disease, cancerous cells are found not only in the skin but also in the bloodstream from where they can settle in other organs.Cancer researchers know that the malignancy of Sézary syndrome is based primarily on the fact that the cancer cells fail to respond to signals that trigger programmed cell death (apoptosis). This makes treatment of this disease particularly difficult because most anti-cancer drugs rely on causing apoptosis.

Karsten Gülow and his team at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg have now succeeded in turning off a specific survival factor, thus driving the cancer cells into apoptosis. In this project, which is funded by the Wilhelm Sander Foundation, the DKFZ researchers collaborated with Jan Nicolay at the Department of Dermatology, Mannheim University Hospital.

"In lymphoma cells, an important cellular 'survival factor' called NFkappaB is permanently activated," Gülow said. "But until now, all tested inhibitors targeting this factor have been too toxic for use as drugs."

For the first time, Gülow, Nicolay and colleagues have now tested an agent called dimethyl fumarate (DMF), which also targets NFkappaB, in cutaneous T-cell lymphoma. A major benefit of this substance is that it is an approved drug for the treatment of multiple sclerosis and psoriasis.

The researchers studied the effect of DMF in T cells that they had isolated from blood samples of patients with Sézary syndrome. They transplanted the tumors cells under the skin of mice, where they grew into tumors. Subsequently, they treated the animals with DMF. After treatment was completed, the tumors grew more slowly and the scientists were able to show that DMF selectively kills tumor cells, leaving healthy T cells unaffected. An even more noteworthy effect was that DMF treatment in the transplanted tumors almost completely suppressed metastatic spread to other organs.

"Our results are very promising," said DKFZ's Peter Krammer. "DMF appears to have at least comparable effectiveness and is better tolerated than most other substances that are used to treat cutaneous lymphomas. Therefore, we have immediately started examining the drug's potential." By now, the investigators have already initiated a clinical trial in collaboration with the working group led by Anne Kuhn from the DKFZ and Sergij Goerdt from the University Dermatology Hospital Mannheim. The trial is supported by the Helmholtz Alliance for Immunotherapy.

Jan P. Nicolay, Karin Müller-Decker, Anne Schroeder, Markus Brechmann, Markus Möbs, Cyrill Géraud, Chalid Assaf, Sergij Goerdt, Peter H. Krammer, Karsten Gülow: Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NFκB.

Blood 2016, DOI: 10.1182/blood-2016-01-694117

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS